Q1 2025 Fresenius SE & Co KGaA Earnings Call
and Sara Hennicken and Sara Hennicken and Sara Hennicken
ннн com
Speaker Change: Good afternoon and welcome to the conference call of Fresenius, Investor Relations, which is now starting. May I hand you over to Nick Stone, Head of Investor Relations.
Speaker Change: With E mail to our distribution list earlier today and is available on <unk> Dot com.
Speaker Change: On slide two of the presentation, you will find the usual safe Harbor statement unless stated otherwise we will comment on our performance using constant exchange rate for sale today.
Speaker Change: Today as usual I'm joined by Michael <unk>, who will take you through the details of another strong performance. We estimate the call will last approximately one hour with the presentation, taking around 35 to 40 minutes with the remaining time for your questions. Obviously to give everyone. The chance to participate please limit your questions to one to two in the first instance, and we can always come back from there.
Speaker Change: Additional round, if needed and with that I'm delighted to hand, the call over to Michael.
Michael: Thank you Nick warm welcome everyone I'm delighted to report a strong start to 2025, another quarter of excellent momentum across our businesses and we reconfirm our full year guidance as always Sarah and I will review, our operational and financial highlights on our individual.
Speaker Change: Within coffee and Helios B.
Speaker Change: Before turning to our results the federal Republic of Germany is starting to have a new chapter a new important political chapter.
Speaker Change: And I congratulate our new Chancellor.
Speaker Change: On his election, and we look forward to working with him and his cabinet, Germany needs strong leadership and a clear growth agenda to improve its competitiveness in a challenging global economic environment. The coalition agreement contained some promising proposal.
Speaker Change: And it is encouraging to see that the healthcare industry is recognized as a strategically important and leading industry in Germany.
Speaker Change: I'd also like to acknowledge the impact of recent global events create uncertainty German fiscal policy change and more.
Chris: Chris It's <unk>.
Chris: Now well positioned to handle these challenges. This is the result of us charging and delivering on future present, yes.
Chris: We've simplified our business structure and increased our ability to adapt enabling us to respond swiftly to a dynamic macro environment. We have created options with competitive operation and a strengthened balance sheet. We now have increased strategic flexibility.
Chris: And the fundamentals that underpin our business aging global population higher prevalence of chronic diseases, increasing healthcare spend and demand for health care workers that remains intact.
Chris: <unk> is a system critical global provider to patients healthcare practitioners and hospitals.
Chris: Our mission remains to save and improve human lives.
Chris: We are committed to lap now.
Chris: Now, let's turn to the Q1 financial results, where you can see our focus is delivering results as always after our prepared remarks, we will have plenty of time for your questions.
Chris: The next phase of future present user rejuvenate has started strongly we delivered excellent results across the company this quarter and we expect this momentum to continue with new products more approvals further efficiency gains and subsequently earnings growth.
Chris: <unk>.
Speaker Change: There are lots of highlights, but let me, particularly mentioned our double digit EPS growth.
Chris: This reflects all our efforts of having turned around our company I E our businesses delivering growth and earnings expansion.
Chris: Our disciplined focus on capital deployment and optimizing our portfolio.
Chris: So as we reduce debt you see this directly affecting core EPS performance up 12% in the first quarter. This will be a source of value enhancement through the rejuvenate face Kabi and Helios both delivered strong top line growth <unk> performance was driven by the increase.
Chris: <unk> contribution from our growth vectors, particularly biopharma, which is moving closer as I've mentioned before two copies structural EBIT margin range of 16% to 18%.
Chris: Overall copies EBIT margin increased to 16, 8%.
Chris: <unk> also had an encouraging start to the year.
Chris: The performance program at Helios, Germany is in early innings, but we cede gradually gaining traction.
Chris: It's about a deepening of productivity and process efficiencies.
Chris: This improves our ability to treat more patients and with better outcomes better patient experiences, while retaining the highest quality in clinical care.
Chris: As announced at our full year results, we've tightened our leverage target corridor to between two five to three <unk> net debt over EBITDA. It continues to be a focus and it's great. We ended the first quarter. After a strong year end finish within the improved range.
Chris: Over the past several years, we've been working very hard to make <unk> better from a structural perspective by selling non core assets exiting vomit and deconsolidation Fresenius medical care in.
Chris: In Q1, we took the strategic decision to significantly reduce our stake in FMC.
Chris: And we used the proceeds to enhance returns lower depth, even further and create value again, it's about moving rapidly to strengthen balance sheet flexibility and improve profitable growth and shareholder return.
Chris: I started my remarks by talking about recent global events.
Chris: And the biggest area impacting the sector the potential ramifications from the recent trade and tariff policies as you know this could affect future economic activity this year and beyond.
Chris: However, we believe we can navigate through this current operating environment.
Chris: On a relative basis, we don't see the same challenges as some of our peers, we have a broad diverse and resilient business with a global footprint.
Chris: As it stands we're able to absorb incremental pressure through the profile and the strength of our businesses.
Chris: Today, we reconfirm, our full year 2025 guidance on the back of 7% organic top line growth and 4% EBIT growth at constant currency.
Chris: Now, let's dive deeper into our core businesses within caviar and Helios, both of which delivered very strong performance in the quarter.
Chris: Starting with <unk> revenues increased by 6% year on year in organic terms fueled yet again by the growth vectors nutrition metric and Biopharma.
Chris: Showed its strength despite a tough prior year comparison as a resilient business, resulting in attractive earnings traction our focus and strategy is obviously paying off.
Chris: Pharma, we have successfully transferred the ownership of our Brazil production site in Annapolis, Hence we are continuing to reduce complexity and streamline our production network further in the U S. We have secured a significant long term award with a major GPO, reflecting the competitiveness.
Chris: Of our offering in terms of both value and quality.
Chris: In nutrition, we strengthened our local capabilities and footprint in China.
Chris: We continue to view as a highly attractive long term market.
Chris: In med tech the ramp up of Avonex, our smart infusion pump is progressing as planned and we are balancing rollout speed and the industrialization of our product manufacturing we.
Chris: We have signed a multiyear contract this quarter with another major U S health institution, and we will continue the expansion and rollout throughout 2025.
Chris: Moreover, we received FDA clearance for our new adaptive Nomogram software, we expect to distribute this to more than 160 U S. Plasma collection centers by the end of 2025.
Chris: In Biopharma the positive momentum continues with excellent organic topline growth and profitability improvements demonstrating very strong incremental margin expansion, which contributes significantly to the overall <unk> margin expansion.
The recent launch of our stickiness biosimilar or tool fee in the U S and EU, along with FDA approval for the newsroom, a biosimilar highlights the strength and the breadth of our portfolio. We now have eight biosimilars approved seven launched into the market.
Chris: On a very positive note the centers for Medicare and Medicaid services CMS issued a permanent product specific billing code for a trophy. The hix fixed code. This designation is an important milestone for broadening access and use supporting quality patient care while concurrent.
Chris: <unk> reducing costs.
Chris: Not at least the <unk> issued a positive opinion on our map science to lose them up so a great performance in Q1, enhancing patient access to innovative affordable treatments for both acute and chronic conditions, we continue to build momentum.
Chris: With advancing the expansion of our growth vectors.
Chris: Staying with Biopharma, let me highlight the tie in ramp up progressing rapidly and in line with expectations showing dynamic month by month.
Chris: We have launched now in more than 20 countries our market share in Europe is supported by incremental tender wins. For example, we achieved an impressive 100% tender win rate in France and are currently winning key regional tenders in the U K.
Chris: In Germany, essentially all sick funds are contracted and in Spain more than 80 accounts are now using <unk>.
Chris: In the U S. <unk> has launched strongly with consistent and dynamic sequential market share growth now at 8%.
Chris: Strategic approach enhance market access and payer coverage efforts continued to drive this substantial gains we now cover around 70% of the IV and 100% of the SC market with our contracts in the second half we will continue to advance the tech.
Chris: <unk> heard to map science and expect a further improvement in market share as Pierre client agreements translate into scripts and patient administration.
Chris: Now, let's move to our care provision platform Helios, which delivered good results and an encouraging start into the year.
Chris: In Germany, we believe the coalition agreement will be positive for us for Helios. It emphasizes a key part of our strategy the clustering and specialization of hospitals, we are already well advanced in the in regard and in that regard and are in a good position to benefit from that development.
Chris: While details remain to be defined it is also a very encouraging sign that the special infrastructure fund will enable investment and support the transformation in the healthcare sector, especially for Hess hospitals as critical infrastructure.
Chris: And efforts to reduce bureaucracy are clear positives.
Chris: Our uncompromising quality focus crystallized, yet again with an impressive number for medical outcomes Helios outperform the German national average in more than 90% of our medical targets moving to Spain, Kieran salutes, our link patient care has.
Chris: Again being recognized externally with 13 of our hospitals ranked among the world's best hospitals in 2025, so congratulations to the team. This is an impressive achievement.
Chris: Really reinforces our commitment to highest quality in clinical care.
Chris: In addition, we're also making significant advancements in digitizing our network the Kieren salute clinics now offer thoroughly.
Chris: <unk> comprehensive digital patient journey now, having seven 5 million patients registered and all of them are benefiting from our digital hospital and very patient platform, which we call Castillo payout.
Chris: Let's discuss the dominant topic for the sector tariffs.
Chris: From an exposure perspective, Fresenius has a diversified portfolio with around 90% of group revenues not exposed to U S. Tariffs. This is underpinned by the exceptionally strong European hospital businesses, which contribute around 60% of group revenue.
Chris: In the U S. We previously launched our more in America manufacturing and supply initiatives. This means that we currently produce around 70% of the medicines, we sell in the U S domestically, including sourcing a significant proportion of high value active pharmaceutical ingredients.
Chris: Our strong local presence includes 4000 dedicated employees and nearly $1 billion invested in U S manufacturing and logistics over the past couple of years overall, we believe this strategic position is a significant differentiator relative to our competitors.
Of whom manufacture their pharmaceutical products outside the U S.
Chris: A central element of our global manufacturing strategy is a long term perspective, maintaining a strong and resilient supply chain for essential medicines and other products.
Chris: A system critical supplier for patient care in the U S and globally, we follow a local for local manufacturing strategy for pharmaceuticals, our largest product segment.
Chris: Significant further investments in the U S are planned over the next five years and we aim to increase the number of employees to further strengthen our footprint in this strategically very important market.
Chris: We have kicked off the rejuvenate phase with a strong momentum and we're excited about how team present US is moving forward together this phase marks a pivotal evolution for our company.
Chris: Right at the start of the future for us and as we defined our core businesses and you see this focus is now delivering quarter after quarter.
Chris: And rejuvenate we want to upgrade this very core we call it upgrading our core and in short it means we keep doing what we're doing but we will do it even better. This is about patient care. This is about customer service and better enterprise processes and operations.
Chris: This is how we already create value day by day. So essentially this is about consistency.
Chris: As we continue to mature as an organization our strategic intent will move to scaling our three platforms specialized biopharma targeted med tech and holistic care provision platform.
Chris: These platforms hold tremendous potential for future growth and innovation by upgrading our core and scaling our platforms. We are laying the ground work to elevate our long term performance.
Chris: <unk> is poised to become a more innovative and relevant healthcare company. Our focus is clear play to our strengths and deliver meaningful healthcare solutions.
Chris: Our journey isn't about sustaining momentum, it's about accelerating and positioning <unk> as a leader in innovation and relevance in our very industry with that I will hand, it over to Sarah.
Sarah: Thank you, Mike and thank you for joining everybody.
Speaker Change: Moving at pace of our future fishing journey.
Sarah: So excellent start.
In terms of financial performance.
Sarah: Our Q1, 'twenty clearly reflect the profound changes we have made over the past two years.
Sarah: And simplification are paying off.
Sarah: We achieved strong organic revenue growth of 7% for the group.
Sarah: EBIT growth was robust at 4% with caviar showing continued strong operating performance.
Sarah: As expected <unk> was affected by the absence of energy released.
Sarah: Against this backdrop, our 11, 6% EBIT margin for the group provides clear evidence of our operational strength and rigorous focus on productivity.
I would like to remind you that we are comparing against an already strong prior year quarter.
Sarah: Aside from revenue and EBIT I am, particularly pleased with the bottom line delivery.
Sarah: Here operating leverage neat focused capital allocation, resulting in a strong EPS growth of 12%.
Sarah: Lower interest expenses.
Sarah: Our deleveraging on the back of excellent operating cash flow in full year 'twenty four.
Sarah: The tax rate was in line with expectations at 25%.
Sarah: Operating cash flow in the quarter improved year on year I will go into more detail later.
Sarah: At three times net debt EBITDA leverage split within the self imposed target range.
Sarah: Positive effects of the Fresenius medical care transaction was partially offset by the cash impact from the completed divestment of Biomet International project business.
Sarah: <unk> continued its strong momentum in the first quarter.
Sarah: On an organic basis revenue grew by 6%.
Sarah: In the upper half of our structural growth plan.
Sarah: This was driven by the growth vector at achieving organic growth of 11%.
Speaker Change: Yes, Biopharma once again stood out with a remarkable 40% largely attributed to the success of <unk>.
Panama remained broadly stable in terms of organic growth against a strong prior year base.
Speaker Change: We saw positive pricing effect in Europe, and the continued competitive environment in the U S.
Speaker Change: Overall pricing effects from Argentina, hyperinflation continue to support cabot's growth rate, but the effect was less pronounced than in the previous quarter.
Speaker Change: We are maintaining our approach is adjusting first tax from highest translation accounting as we did in full year 'twenty four.
Speaker Change: On the profitability side Cabot delivered an excellent EBIT margin at 16, 8% with year on year margin improvement across all business units.
Speaker Change: The significant margin expansion and impressive 16% EBIT growth at constant currency reflect volume effects and continued improvements in our cost base.
Speaker Change: The growth vectors, we are leading the way with the 390 basis points increased to 15, 3% driven on a broad based positive development and again, an outstanding performance at Biopharma.
Speaker Change: The pharma margin was off.
Speaker Change: Also in <unk>.
Speaker Change: 150 basis points year on year to 22, 9%.
Speaker Change: Turning to Helios and.
Speaker Change: A very strong 8% organic revenue growth driven by strong activity levels and positive pricing effect.
Speaker Change: From a year over year perspective, Q1 also benefited from the Easter effect falling.
Speaker Change: Falling in the second quarter this year.
Speaker Change: EBIT margin came in solid at nine 8%.
Speaker Change: We expect this softness due to the absence of energy release in Germany was partially compensated by excellent profitability in Spain.
Speaker Change: Let's take a look at the business unit.
Speaker Change: <unk>, Germany strong organic growth was driven by price effects.
Speaker Change: Admissions and case mix, both showed a positive development as well.
Speaker Change: <unk> year on year due to the energy released EBIT margin in Germany improved sequentially versus Q4.
Speaker Change: Driven by the strong topline and supported by contributions.
Speaker Change: Contributions from the performance program.
Speaker Change: We continue to expect the ramp up of the performance program with more significant EBIT contribution for the second half of the year.
Speaker Change: <unk>, Spain once again delivered a strong print organic growth was driven by strong activity levels and favorable price effect.
Speaker Change: They achieved a 13, 1% EBIT margin and an outstanding 23% EBIT growth at constant currency also helped by the Easter effect.
Speaker Change: Congratulations to the team for this excellent operating performance.
Speaker Change: A seasonally weaker quarter Q1, 'twenty four 'twenty five operating cash flow was a step up to prior year.
Speaker Change: Germany in particular contributed with strong operating cash flow driven by accelerated nursing budget negotiations and optimize invoicing processes.
Speaker Change: At Kirby our capital efficiency focus helped to mostly offset higher prepayments and some phasing effects.
Speaker Change: Based on last 12 months' numbers, we saw an impressive increase of free cash flow of almost 2 billion euros.
Speaker Change: Given by our successful working capital measures and Capex focus.
Speaker Change: Please be reminded that the dividend suspension 'twenty 'twenty four is still reflected here.
In March we took another decisive step in future FID by selling 10 6 million shares of Fresenius medical care in an accelerated book building.
Speaker Change: Currently we issued an exchangeable bond maturing in 2028 with another $10 4 million Fresenius medical care shares underlying.
Speaker Change: The combined transactions generated approximately $1 1 billion.
Speaker Change: Gross proceeds for <unk>.
Speaker Change: Only the proceeds from the share sale amount.
Speaker Change: [noise] amounting to around $500 million are included in the free cash flow bridge.
Speaker Change: While the approximately $600 million from the bond issue are shown as cash flow from financing activities.
Again, great ongoing cash flow delivery very proud of our team driving the stringent cash flow focus.
Speaker Change: Our capital allocation strategy as a centerpiece of our financial agenda as they move into the rejuvenate Kay.
Speaker Change: We will ensure that we continue to deploy capital in a focused and value accretive way.
Speaker Change: Our approach is based on three priorities.
Speaker Change: First investing in the business to drive.
Speaker Change: Sustainable long term growth upgrading the core and scaling the platform.
Speaker Change: Second delivering attractive shareholder returns.
Speaker Change: And third further strengthening the balance sheet.
Speaker Change: The SME transactions aligns perfectly with these priorities.
Speaker Change: Let me remind you where we are coming from.
Speaker Change: Two years ago, we were around four times net debt to EBITDA.
Speaker Change: <unk> expenses were a significant drag to our financials.
Speaker Change: And we literally did not see net income growth for years.
Speaker Change: We deliberately did not catch the F&B stake that focused on improving our own operational strength.
Speaker Change: Had with rigorous cash focus.
Speaker Change: This allowed us to deliver negative phasing of structurally and sustainably stronger.
Speaker Change: From that position of strength, the SME transaction now allowed us to capitalize on SME its share price gain.
Speaker Change: The exchange of a bond with a premium of 30% enabled us to realize future value creation, while providing cost effective funding at zero percent coupon.
Speaker Change: Congratulations to the team for the successful execution.
Speaker Change: These transactions have strengthened our balance sheet and help deleveraging further.
Speaker Change: Refinancing needs for full year 2025 has been reduced materially.
Speaker Change: It also provides the basis for continued bottom line growth.
Speaker Change: Interest expenses will be improved by approximately $30 million to $40 million on an annual basis.
Speaker Change: Corresponding to around four to five on EPS level.
Speaker Change: But this year, we're talking about a reduction of around 20 million Euro.
Speaker Change: Clearly underscores the value accretive nature of the transaction.
Speaker Change: Based on the strong start to full year 2025, we are confirming our full year guidance.
Speaker Change: When we gave guidance in February we acknowledged the fast moving macroeconomic and geopolitical environment.
Speaker Change: I think in a higher level of operational uncertainty.
Speaker Change: Our guidance continues to reflect current factors and know and uncertainty such as potential impacts from.
Speaker Change: Our peers and the health care sector as a whole.
Speaker Change: Although not completely immune to tariff opinions as to that position today with its diversified portfolio underpinned by a strong European hospital business.
Speaker Change: So Germany in the first nine months of the previous year.
Speaker Change: Easter FX fall into Q2 this year.
Speaker Change: And we expect a negative impact from the Kato EVP in China to start in the second quarter.
Speaker Change: Adjusted <unk> as a nutrition therapy for patients with impaired kidney function.
Speaker Change: Q2 on a standalone basis, we currently expect an impact in the low to mid double digit in revenue and low double digits on EBIT.
Speaker Change: I would also like to mention that while our guidance is given at constant currency. The recent weakening of the U S. Dollar against the Euro would obviously have an impact on our reported numbers. If it will remain over the course of the year.
Speaker Change: More broadly.
Speaker Change: FX rates would stay on the current level for the full year, we would see a negative effect of roughly 1% on reported revenue and roughly 2% on reported EBIT.
Speaker Change: Last but not least while we do not guide EPS growth, we still want to update you on the assumed level of interest expenses for the full year.
Speaker Change: Given the expected positive effects of the F&B transactions and our lower debt level. We now expect lower interest expenses in the range of 370 to 300 million Euro 90 million Euro.
This will provide a nice backdrop.
Speaker Change: Granted with today's strong Q1 print we're set to bring our performance to the next level as we move forward with rejuvenate.
Mike: With that I'll hand back to Mike.
Mike: Thank you Sarah we have started a new phase of future presenters rejuvenate with great momentum.
Speaker Change: We had an excellent start to the year and present it.
Speaker Change: Very well positioned to maintain this very momentum and to continue creating value for our shareholders.
Speaker Change: Operating in the resilient and growing healthcare industry presented is well positioned across very attractive markets, we simplified our structures and increased agility, enabling us to response.
Speaker Change: Excuse me full house for a moment.
Speaker Change: Excuse me I believe we will switch to another line just a moment please.
Speaker Change: Okay.
Scott: Thank you Scott.
Speaker Change: Thank you apologies just one moment please.
Speaker Change: Okay.
Speaker Change: [music].
Speaker Change: Okay.
Speaker Change: Yeah.
Speaker Change: Okay.
Speaker Change: Okay.
Speaker Change: Yeah.
Speaker Change: Yeah.
Speaker Change: Okay.
Speaker Change: Okay.
Speaker Change: Okay.
Speaker Change: Okay.
Speaker Change: Excuse me Michael you May.
Speaker Change: Yes resume once again apologies please continue sir.
Speaker Change: Okay, Hello, everybody on the call apologies for this Meanwhile, also found out that there was obviously we were breaking up.
Speaker Change: Two three times during <unk> and my <unk>.
Speaker Change: Presentation, so apologies for that one I think the numbers speak for themselves but.
Speaker Change: I think we can catch up on the Q&A. So my last not famous last words, but last which will be our strengthened balance sheet gives us exactly that the options and we have the flexibility to adapt to everything we do is essential as a system critical health care provider we are.
Speaker Change: Part of the solution with healthcare demand rising globally, <unk> is uniquely positioned to deliver impact where it matters, most and now I think Nick let's move into Q&A.
Andrew: So Andrew over to you. Please.
Speaker Change: We are now starting the question and answer session if you'd like to ask a question. Please press star followed by one on your Touchtone telephone the operator will announce your name when it's your turn to ask a question.
Speaker Change: Makes you wish to cancel your question. Please press star followed by June.
Speaker Change: The first question is from <unk> <unk> with Citi. Please go ahead.
Speaker Change: Hello, Bob.
Michael Sarah: Michael Sarah and thank you good afternoon, and thank you for taking my questions I will keep it to two please.
Michael Sarah: My first one is on the Biopharma.
Speaker Change: Yes, Michael Thank you for the color to say that the business is approaching.
Speaker Change: Corridor of Kabi, I guess I'd love to get your thoughts on what do you change.
Speaker Change: We do get that.
Speaker Change: We do get that.
Speaker Change: Margin in that corridor, Ed what is the sort of revenue trigger point that we need to be thinking about to start seeing margins that are just in line with carbon but maybe in line with the U S coffee business.
Speaker Change: That would be Super helpful. And then my second question is on the deleveraging and congratulations on the progress that you are making here good to see that.
Speaker Change: I guess Sean.
Speaker Change: To what extent.
Speaker Change: And we anticipate more active balance sheet management farm you all that's probably a question for Sarah Thank you guys.
Speaker Change: Let's start with Chuck.
Chuck: Sure happy to start with the deleveraging.
Chuck: So I think if you think bigger picture in terms of portfolio I think that one were gone with at large it will see us simplifying here and there a little bit as Michael alluded to what we have seen on the pharma side this quarter.
Chuck: But on the bigger picture on portfolio. We're basically done now if you think on deleveraging I think we made the more than 70 basis points last year that was a tremendous step downward don't expect that speed to continue in 2025, because look we have achieved by our clear focus on cash and in particular in networking capital.
Chuck: As a management we have obviously worked on all metrics I E days payable inventory and so on we have optimized all of that so there will be incremental incrementally getting better and the focus on cash will remain.
Chuck: We have seen.
Chuck: In Q4 in terms of additional cash generation, resulting in that step down on deleveraging you will not see in 2020, having said that we obviously, we remain fully focused on balance sheet deleveraging and we have given ourselves the lower range of twin hop to suite and we are fully focused on getting within that frame.
Chuck: Further down towards the.
Chuck: The mid to bottom end of what we communicated and delivers a clear focus on cash.
Chuck: And at the same time, improving our EBITDA further.
Ankur: Hey, its actually endeavor Ankur hi, there Michael.
Ankur: It was an attempt to find out whether we would monetize more on the investments.
Ankur: So this is not a discussion we just.
Ankur: <unk> delivered on that in Q1 now.
Ankur: Now on the Biopharma look as much as I understand the eagerness I think we need to take it step by step.
Ankur: We will update you as much as we can also with transparency going forward. How this business is progressing and what you get out of what we've been saying is it will also be progressing nicely going forward last year last fiscal year was still an investment case. This was hardly making money. So we were talking about EBITDA breakeven.
Ankur: And we're getting the EBIT line. This year as said they are approaching the 16% to 18% by the way to 60% to 18% already was hyped up when we introduced the new fiscal 'twenty five or the new rejuvenate face. The reason for that also being that this is the margin band.
Ankur: Or let's say a more midterm profitability pool, which then reflects the potential we see in the Biopharma business now.
Ankur: Now great progress, we see we said.
Ankur: The last time mid term its going to be in the range mid term usually is three to five years and the last road show I think I said, probably we think if everything works, we will work against more on the three year horizon, but we will update you step by step. We also said that over the course of.
Ankur: Probably the next two and a half years this business can be a $1 billion.
Ankur: Euro depending on where the priority stance.
Ankur: Business and it is also a function of the molecules hitting the market and then being executed one of the great things you see in Q1 is exactly that we are placing more molecules in the market. We have as I said, a couple of active molecules in the market.
Ankur: Part of them really being already revenue carriers. So this is the way we want to take you along the journey.
Speaker Change: Understood. Thank you guys so much.
Ankur: Okay.
Ankur: The next question comes from.
Ankur: Oliver Rheinberger with copper shell.
Speaker Change: <unk>. Please go ahead.
Speaker Change: Thanks, very much for taking my questions two if I may.
Speaker Change: Mike in your prepared remarks, you talked about the kind of increased balance sheet flexibility. So I was just wondering if you can provide an update.
Speaker Change: If you would to future capital location, which franchises would be a priority for you in particular can you comment whether you would be willing to also do larger capital deployment to biosimilars and any thoughts if there's any kind of evolve for nutrition that will be question number one and the second question just on German Helios B.
Speaker Change: The margin improved sequentially, but year on year seeing were done.
Speaker Change: By one three percentage points I guess energy relief can probably explain part of it but obviously there was also the support from Easter.
Speaker Change: Trying to get the kind of feeling is there any kind of other moving parts in the eastern now occurring in Q2 can you just give us any kind of flavor of where that kind of Germany gross margin may come in just to get the numbers in the right ballpark. Thanks, so much.
Oliver Rheinberger: Yes Oliver.
Speaker Change: Start with the first one.
Speaker Change: First of all the priorities on capital allocation.
Speaker Change: Particularly from a financial point of view of Sarah outlined I think quite nicely and this is exactly to the disciplined framework. We're working concurrently obviously the flip side of a financial thing is the strategy and the strategy is clear now that we defined our core we have a lot of businesses, which are in attractive markets.
Speaker Change: Our goal is to scale those businesses scaling in today's world means that you need to work and ecosystems.
Speaker Change: Not necessarily immediately lead to M&A, but it can also needs to lead to a capital commitment. So on the Biopharma platform. It is.
Speaker Change: In all of these businesses, which bio pharma platform. Its biopharma. It is the IV generics and it is nutrition. This is about innovation. This is about pipeline. This is about new molecules. It's about in licensing for example, and then you see capital commitment.
Speaker Change: And this is true for all of the businesses, if and when an opportunity like that arises we look at the risk reward profile will look at the individual business plan. So it is a theoretical question at a theoretical answer but what I am trying to say is this is exactly where we got to put our money to scale. These platforms also in the Biopharma in the Newton.
Speaker Change: Christian as well if you have a great idea for an asset welcome.
Speaker Change: They are not too many assets out there is the beauty of exactly that market, but theres a lot of dynamic happened there happening there and Thats why we said also for this year part of the capital allocation and nutrition goes to R&D.
Speaker Change: And also increasing the pipeline.
Speaker Change: On medical Technology, if you look where we are particularly with the infusion systems, we R&D E. R. R in ICU and everything which makes logical sense to.
Speaker Change: Attach something to it and is promising and scaling that is what we're doing on the care provision platform. It is about digitizing don't forget <unk>, they're already last time I reported 7 million users. This time I reported $7 5 million users and this can be further scaled minimally in Spain and <unk>.
Speaker Change: <unk>.
Speaker Change: I think so.
Speaker Change: I'd be happy to take it.
Speaker Change: Look I think probably you want to you want to separately.
Speaker Change: Look at U S, Germany, and then Q1 because that currently performing on very different levers. If you look at Q1 that I would say the Easter effect was more pronounced in not only this year, but also if you look back.
Speaker Change: Last year, and then looking at that that a very strong Q2 of last year.
Speaker Change: The benefit of Easter in Q2 last year now this year, it's the reversal and that have had a very strong.
Speaker Change: First quarter with a 13% margin.
Speaker Change: If you look at <unk>, Germany never seven 7% margin.
Speaker Change: And we always said that they need to run faster to keep the ground. This is one of the reasons why they initiated that performance program, which we always said is going to be more back end loaded. We do see initial positive signs. We feel we are on track to achieve that performance program, but some of the measures obviously will come.
Two question more on the second half of the yet. So you can expect that Germany, you will see an uptick in margin compared to your Q1 performance and also there. If you look between Q1 and Q2, the Easter effect is not as pronounced as on the as on the coupon side.
Speaker Change: Perfect. Thanks very much.
Hasan: The next question comes from Hasan <unk> with Barclays. Please go ahead.
Hasan: Hi, Good afternoon. Thank you for taking my questions two please.
Hasan: Firstly on kabi, great to see some really strong progress on the margin, particularly the growth vectors.
Hasan: As biopharma enters the range over the coming years and nutrition remains accretive as you've talked about.
Speaker Change: Can you talk about what is needed to get med tech into the range and if anything inorganic is required to your mind to scale this business and get it into the range.
Speaker Change: And then secondly, if you could talk a bit about progress on the tech transfer of tie in last quarter, you talked about tie in revenues being 90% contracted for the year, but.
Speaker Change: You clearly needed to manufacture and ship explaining some of the guidance range. So.
Speaker Change: How confident are you on the latter piece today. Thank you.
Speaker Change: Thank you Hassan.
Speaker Change: Great question, let's start with the latter one I mean.
Speaker Change: It's actually only a couple of weeks between.
Speaker Change: Last time, we spoke at the year end earnings call. So nothing has changed on that one we are in the mid of the tech transfer.
Speaker Change: Is.
Speaker Change: An intense process, because there's a lot of documentation and regulatory approval needed for that one.
Speaker Change: As I outlined the last time initially when we had.
Speaker Change: Bought the majority stake of map science, we didn't even plan for having tie in on map signs now that the demand is working that nicely. This is what we are speeding up. So that's why the message is the same that first of all the tech transfer is.
Speaker Change: It's happening as we speak.
Speaker Change: Don't see any hiccups, but it will take its time. So therefore, the bigger pickup of Thai yen will still be in Q3 and Q4. So nothing has changed in terms of phasing vis vis what we what we had last time. So on your other question. It's a very good question.
Speaker Change: These were very blunt that metric is below the blended margin band of the blended profit pools, we see there.
Speaker Change: And where it stands on an EBIT basis, it will probably stay below but the clear goal, which they also are committed to in the capital market day that it needs to improve.
Speaker Change: By that as such it is creating value because it is early earnings growth and it's getting to a higher quality earnings profile. If you would look at it from an EBIT basis.
Speaker Change: Then probably it looks much better because of the of the past kind of acquisitions.
We had there.
Speaker Change: Perfect. Thank you.
Speaker Change: The next question comes from.
Speaker Change: It does.
Speaker Change: <unk> with HSBC. Please go ahead.
Speaker Change: Hi, Thanks for taking my question.
Speaker Change: On the corporate restructurings, you seem to have a lot of corporate restructuring this quarter. So.
Speaker Change: The impact on net income level and not on EBIT.
Speaker Change: Just wanted to see the nature of these and what's the outlook for the coming quarters, how much more do you expect and what are the underlying steps you have taken recently and others that you are still expecting to take.
Speaker Change: Yeah happy to take that look I think you're probably referring to the special items below the line.
Speaker Change: So that is basically.
Speaker Change: By the continued exit from Barnett.
If youll be reminded we have sold our international contract business and we also closed in Q1, so signed and closed all in one quarter, which means that moves into first discontinued and now its closing out.
Speaker Change: And that is the roughly $230 million you see that.
Speaker Change: In addition, obviously there are some smaller assets on cost and efficiency.
Speaker Change: Key transformational one.
Speaker Change: I would say the largest part is Amit now we have ticked the box on the biomet topics.
Speaker Change: International Project business was the last piece the last big piece to be solid.
Speaker Change: When we initially announced that we're going to discontinue a bond that we said that for the international.
Speaker Change: International for the wind down of the International project business, we calculated.
Speaker Change: High triple digit million amount.
Speaker Change: Now if you look full year 'twenty four it was roughly $470 million and now you can add the 230, which brings you roughly.
Speaker Change: 700, <unk> there will be some remaining costs ongoing as we really close out and clean up some remaining activities, but acknowledge that.
Speaker Change: Very reassuring.
Speaker Change: The next question comes from James Vane Tempest with Jefferies. Please go ahead.
Speaker Change: Hi, Thanks for taking my question just one Ashley.
Speaker Change: I guess the Q1, you are trending above the top end of the guidance and you had mentioned momentum is going to continue so.
Speaker Change: So what would you need to see for you tell the confidence to raise guidance for first half. Thank you.
Yes look.
Speaker Change: I understand all the excitement but.
Speaker Change: All of us read the <unk>.
Speaker Change: This is a very dynamic environment.
Speaker Change: And I think.
Speaker Change: If I compare and contrast, our statements in the current earnings season with a lot of companies.
Speaker Change: We reiterated our outlook.
Speaker Change: And.
Speaker Change: It is also the range, which we spend in.
Speaker Change: A couple of weeks back so is this.
Speaker Change: On the on the EBIT side, the 3% to 7% growth.
Because theres a lot of moving parts already last call, we said and I said nothing changed there are still things to come in the less later half of the year.
Speaker Change: Sarah alluded to Helios, Germany, and I think it was Oliver who will also ask.
Speaker Change: And the question was right there is the missing energy relief and if you listen to the tone.
Speaker Change: We still need our colleagues at Helios to ramp up their efforts so that the real savings hitting the bottom line hitting the P&L.
Speaker Change: I have to come and have to ramp up during the course of Q3 Q4 next quarter and we have been very transparent from the outset there is quito.
Speaker Change: Which is a very high margin kind of product in China. So this contribution.
Speaker Change: Not only the revenue, but the high gross margin.
Speaker Change: Yes.
Speaker Change: Not there anymore from Q2 onwards, yet.
Speaker Change: If I look at the margin of <unk> last year 15, 7% and then we said 16% to 16 and a half. This is already an improvement yes. It's great that we have a great start at 16, eight but <unk> is going to come in Q2, and then don't forget Q3.
Speaker Change: Is the seasonality.
Speaker Change: Quarter four the hospital business. So if you take all of this together.
Speaker Change: I think we get more clarity.
Speaker Change: And this is without any geo economical effects when we go through quarter three.
Speaker Change: Many thanks a lot.
Victoria Lambert: The next question comes from Victoria Lambert with Bahrenburg. Please go ahead.
Victoria Lambert: Thank you I've got two questions. The first is just on your generic buyers similar.
Speaker Change: Do you have the necessary reimbursement cards, I think sandoz was talking about having a cute.
Speaker Change: <unk> colored in that that takes a few months.
Speaker Change: To get that for full reimbursement.
Speaker Change: And then the second one is just if.
Speaker Change: Yes.
Speaker Change: <unk> situation in the U S has impacted.
Speaker Change: Our expansion plans for nutrition I know you guys were wanting to grow in that market. So just wondering if you're thinking of.
Speaker Change: On.
Speaker Change: Increasing.
Speaker Change: Our local presence.
May be through M&A or partnerships.
Speaker Change: Thank you.
Speaker Change: Yes, Hi, Victoria look on the on the.
Speaker Change: Nutrition business.
Speaker Change: We like what we see in the U S. This is growing also in Q1 growing and having a nice margin, but we have been very candid that it is.
Speaker Change: From a very low base so in the greater scheme of things it will not move the needle.
Speaker Change: It has always been the discussion how can we get to a larger footprint into the U S.
Speaker Change: And if you don't make an inorganic move which is not on the agenda. Currently then this is the slower.
Speaker Change: Slower maybe less risky way to do that so thats not that much from from the from the tariff side on the nutrition business.
Speaker Change: When it comes to.
Speaker Change: Dana you're right in the process of everything you need the code Thats why I was so happy to report in my speech that we have the billing code or <unk> code for <unk> and that always takes some time remember on Pepsi leap two months, we had the approval in Q2 last year, then we said in Q.
Speaker Change: Three we got the billing code and then you can start commercializing and also from a regulatory point of view you need to comply with these regulations not starting before you have the code for example on market access and the like and then proxy we started selling.
Speaker Change: In December that same is true for <unk>.
Speaker Change: You didn't ask about <unk>, but that is just to give you a flavor also that one is more backend loaded we now have the code. We can now start commercializing nelligan.
Speaker Change: Talk about market access and on de La This will still take some time to get the FDA approval. So we need to take the next next step, but everything as I said to <unk> question is actually working like clockwork.
Speaker Change: One molecule after the other is hitting the market.
Speaker Change: <unk>.
Speaker Change: And it never answer a question, which has not been asked but I'll do it anyway.
Speaker Change: You look at the at <unk>.
Speaker Change: Margin of bio Parma in Q1.
Speaker Change: You, usually ask us about milestone payments.
Speaker Change: Last year.
Speaker Change: Millstone payment were roughly $15 million $15 million to $20 million I think $50 million higher than this Q1.
Speaker Change: We are already missing $15 million milestone payment from map science, yet you see this tremendous margin expansion and this is a function of one thing hitting the market as to the other.
Speaker Change: Okay. Thanks, that's super helpful.
Hugo Solvay: The next question comes from Hugo Solvay with.
Speaker Change: BNP Exxon. Please go ahead.
Hugo Solvay: Hello.
Speaker Change: Congrats on the <unk>. Thanks for taking my questions I ask two please.
Speaker Change: Maybe Michael B Pictures on Med Tech or how should we think about the importance of future contracts for our future growth.
Speaker Change: They are more one offs here and there or would you expect to see more coming through as you build the portfolio and someone may be multiple Sarah.
Speaker Change: Interest expenses in Q1, you're running well below the run rate implied like in Orlando, the screens with <unk> $390 million range, which you have lower for the year could you talk about staging for the remainder of the year. Please.
Speaker Change: Thank you Laura that French by $30 million at the midpoint gets you mentioned the $20 million.
Speaker Change: But from lower leverage so just can you quickly elaborate.
Speaker Change: Onto dry vessel for the 10 million data. Thank you.
Speaker Change: Yeah, Let me, let me maybe comment on the new interest expense range, a little bit. So first of all is obviously.
Speaker Change: Driven by the execution on the sale of SME Sherry.
Speaker Change: Which brings us down to the roughly $20 million as I had in my script as well and then we start at a low.
Speaker Change: Lower overall debt level this year and that gives us more flexibility in order to reduce our interest expense. So that when we entered the year with $2 3 billion of refinancing ahead of US obviously with the SME transaction that became materially lower.
Speaker Change: We also have a dividends ahead of us in May however.
Speaker Change: Have already repaid.
Speaker Change: The maturities we have already repaid one instrument one other also coming up in May and then a smaller one in between and then allowed Cherry zero coupon bond in October. So there are lots of moving pieces.
Speaker Change: However, we feel very confident with the leverage level, we have achieved and what we currently see in terms of interest rate environment.
Speaker Change: That we will be able to deliver within that range.
Speaker Change: Sure.
Speaker Change: I hope that answers your question.
Speaker Change: And so it's hard to understand a little bit on where you were driving at but I hope that was the essence of what was lost Paul.
Speaker Change: Yes.
Speaker Change: Okay.
Speaker Change: And I had the same thing.
There was some noise in the line I don't know whether I got you correctly I heard med Tech one offs and so on well since we are not talking about the charges or cost one off.
Speaker Change: I assume you probably mean the business continuity or sustainability.
Speaker Change: Gaining contracts.
Speaker Change: The first message and maybe this answers a little bit the question, where does the margin of medical or why do we believe they can improve the margin and getting to higher profit pools.
Speaker Change: We're talking about long term contracts, they're long term contracts, where you are very close to procedure growth and then recurring revenue because you sell consumables.
Speaker Change: In the case of Avonex for example, but also the normal Graham on the on.
Speaker Change: On the plasma side. It is software and then software revenue as you know usually has a higher margin.
Speaker Change: On the on the pump business on the Avonex, but also on the general on the pump business. It is about rolling out and building an installed base. Once you have an installed base, it's pretty much an asset where you can sell consumables into and at some point in time software and software upgrades, so very stable.
Speaker Change: Contracts long term contracts.
Speaker Change: And then building out an installed base. This is the strategy, which we have there.
Speaker Change: Given the.
Speaker Change: People poll for questions, we'll take another 15 minutes.
Speaker Change: As many of those as we can.
Speaker Change: Apologies in advance if we don't make it.
Thank you. The next question comes from Oliver Metzger.
Jeff: Jeff. Please go ahead.
Oliver Metzger: Good afternoon. Thanks for taking my questions first one on Helios, Germany. So you made a comment on positive price effects.
Oliver Metzger: How temporary are they in nature, so should be.
Oliver Metzger: Back to similar contribution for the next quarters.
Oliver Metzger: Some questions on Biopharma you also mentioned earlier strong contribution of <unk> biopharma growth.
Speaker Change: Can you give us a little bit more.
Oliver Metzger: Feeling Ware Grove.
Speaker Change: <unk> Biopharma would have been.
Speaker Change: Excluding <unk> so for the remaining portfolio. Thank you.
Speaker Change: Maybe let me start with Germany, so that pricing is predominantly driven by the Doj and this data which is set at Cove point and that will obviously continue for the remainder of the year.
Speaker Change: Yes.
Speaker Change: Pretty sustainable on the Biopharma.
Speaker Change: Not quite sure where youre.
Speaker Change: Hi, Ann is embedded and integral part we spend a lot of money in the development phase so.
Speaker Change: I don't see any reason it taking out <unk> out of our numbers.
Speaker Change: You want to get to how all the others are doing I think.
Speaker Change: It is clear we have always been saying that especially in the U S industrial.
Speaker Change: A different play while the limo masked by the way. We also said that on that one we're going down a different route we're doing private label deals and on branded.
Speaker Change: More on other remote Acs then maybe on the branded industrial and then.
Speaker Change: Told you on math science.
Speaker Change: Element milestones, we're missing, but yes, they were growing and they were growing nicely. So on their on their end is beef up about it tomorrow, which is.
Speaker Change: Commercialized by a third party.
Speaker Change: But also on industrial by the way on a global basis, we have been growing and Thats, what I mean.
Speaker Change: We have <unk>.
Speaker Change: Green gas theme with little tough in the U S. We have industrial worldwide, we have tie and we have <unk>, we have <unk> from upside with sticky no map is coming they loosen up is coming.
Speaker Change: We had struck with deal.
Speaker Change: On the Biosimilar for EMEA and this is how it is going to work going forward.
Speaker Change: Forward.
Speaker Change: Okay.
Speaker Change: Thank you.
Speaker Change: The next question comes from Marianne below with Bank of America.
Speaker Change: Please go ahead.
Marianne: Good afternoon, and thank you for taking my question and the first one on <unk> you had a good market share pick up in the U S. Europe stayed a little bit flatter. So just wondering how that's translating to growth contribution from both region for Titan.
Speaker Change: We give a little bit more color on the split here and going forward.
Marianne: And my second question is on the F&B stake you have.
Marianne: <unk> lowered your stake in <unk> into the quarter, but still have an unfortunate ownership.
Marianne: Just wondering if you would be open to lower is it further in the future and what could be the reason behind it.
Marianne: Of the stake or part of it.
Marianne: Thank you.
Marianne: For the sake of short Marianne on the latter one.
Marianne: There is no intention.
Marianne: Did the transaction solely a couple of weeks ago.
Marianne: <unk>.
Marianne: We believe it's pretty meaningful by the same token we did say and this is important that we believe can further value creation in that asset Thats why we believe it was a smart transaction with the exchangeable. We also believe that they can create value and then we participate also from the upside.
Marianne: The hope.
Marianne: Hopefully it goes beyond the implied price we have in the in the exchangeable and on top of it we still have the remaining stake.
Speaker Change: Which then as you say there is no triggering event.
Speaker Change: In terms of there is an arithmetic or something like that but.
Speaker Change: <unk> two maybe many others, we have that flexibility and that gives optionality and asset stability and that makes us feel good.
Speaker Change: Then on the on tight tie end.
Speaker Change: Strong pickup.
Speaker Change: As I said in.
Speaker Change: In my speech incremental tender wins also in Europe.
Speaker Change: Almost I would say mushrooming in every country and you need to see where you are.
Speaker Change: Where and how you bid because we want to when I get to the market share and.
Speaker Change: Have those I think it's in the presentation 22 countries that top eight countries. So we just recently won in France.
Speaker Change: Yes.
Speaker Change: In the U S. We're making good inroads I told last time that we have good visibility on the contract now I would even say we have.
Speaker Change: Complete visibility now it's more what has answered on delivery and obviously if and when.
Speaker Change: We would need to allocate we look at.
Speaker Change: At our customers and where we have good book of business.
Speaker Change: So other molecules this as well.
Speaker Change: Where would go first.
Speaker Change: Great. Thank you very much.
Speaker Change: The next question comes from Robert Davies with Morgan Stanley. Please go ahead.
Robert Davies: Yes. Thanks, you only got one left most of them have been asked.
Speaker Change: Just on the <unk>.
Speaker Change: Margins in <unk>, Germany.
Speaker Change: Germany, perhaps you could just give us a little bit more color in terms of where we are on German hospital utilization trends I know that was something you.
Speaker Change: You highlighted in your capital markets day, as a part of your margin expansion.
Speaker Change: So the strategy and I guess within that question.
Speaker Change: Is there sort of a threshold a level, we need to get to.
Speaker Change: To get margins back into the 11% to 12% band beyond this year I know you've got the headwinds you've called out already for this year I'm thinking of sort of 26 and beyond thank you.
Speaker Change: Yes happy to take.
Speaker Change: I mean.
Speaker Change: That's very obvious.
Speaker Change: Where we see the strongest uptake is if we see that strong activity call. So whenever we see stronger activity growth.
Speaker Change: Clearly have significant more significant or material impact given the infrastructure, we have and we operate now I think it's fair to say while in Spain.
Speaker Change: You'll see us doing green tiers here and there I think in generally need the infrastructure is more stable and thus it is about the topline growth, we generate above and beyond the pricing impact to leverage that infrastructure, which we have.
Speaker Change: I think part of the performance program, which we have launched is exactly addressing that be it on the clinical processes and optimizing clinical processes. When it comes to emergency room, ICU clustering strategy, how would we actually.
Speaker Change: Manage the patient in the hospital, if you so wish and how we enhance the patient experience and also the treatment for the patient directly directly related to our infrastructure. But then also in the non patient paced English is the second kind of a big market.
Speaker Change: Our performance program, which is how do we optimize all of the processes, which are non client non patient facing an.
Speaker Change: Digitalization strategy, it infrastructure and one and all of that when we get that one right and we deliver on outcomes program that will give up on a better footing on a different cost basis also to manage that infrastructure. When we move into 2026, but you will see that for.
Speaker Change: 25 to come back to this year, you will see that margin.
Speaker Change: The appreciation on the heels of Germany side that Q1, we were at nine point.
Speaker Change: <unk> guidance for the year to say around 10, but not below 10.
Speaker Change: Gives you an indication as to what our ambition is for this year.
Speaker Change: Relative to M&A.
Michael Sarah: If I may add next to what Sarah said on top if you think about because you were asking about 2006 and beyond.
Michael Sarah: It is the clustering strategy at the end of the day is how you also cluster and specialized your infrastructure if you switch and then.
Michael Sarah: Manage populations as to where do we get the biggest bang for the Buck at the end of the day.
Michael Sarah: In which hospitals can be do what were very good and this coincides also if and when the hospital reform is being continued by the new government. This is another structural driver to everything Sarah outlined.
Michael Sarah: That's very clear thank you.
David: The next question comes from David.
David Adlington: Adlington of Jpmorgan. Please go ahead.
Speaker Change: Hey, guys. Thank you want on Helios more and call me. Please.
David Adlington: On Helios.
Speaker Change: Wanted to given the fall in energy prices and oil back to sub 60 Bucks.
David Adlington: If you would like to see.
Speaker Change: I mean, I know you got some hybrid type of hedging contracts any tailwind from falling energy prices anytime soon and it could be able to quantify how.
David Adlington: How much those might come in.
David Adlington: And then secondly on coffee, obviously strong start on the margin up 170 basis points in the first quarter.
David Adlington: Guidance I think before you had 30 to 80 basis points of expansion.
David Adlington: I'm just wondering if you could help give us some help into the cadence of margins through the rest of this year.
David Adlington: Yes, David.
David Adlington: I'll start off.
David Adlington: To start on the energy so in generally we do long term energy contracts and we hedged quite a significant cushion and so we are in for a longer term, which kind of protected us when energy prices rose materially, but which also means we're not directly linked to shorter term changes in energy prices and I think next to it at all.
David Adlington: So fair to say there is a full basket of other material costs as well as driving our overall cost base.
David Adlington: So managing that compared to the increase in <unk> is one of the key tasks at hand for the he is Germany.
David Adlington: And by the way I'm not.
David Adlington: That deep into the energy business anymore, but as far as I know German base load in the market is not pack to oil prices.
David Adlington: Rather a function of the merit order and not so much of the oil price.
David Adlington: On coffee I think we outlined that are ready to $16 eight is really phenomenal.
David Adlington: We just mentioned that it's even stronger when you wouldn't counter those.
David Adlington: Of those milestone payments from <unk> Q2, again key tool will be missing.
David Adlington: Sarah mentioned this one in terms of growth.
David Adlington: Do the same thing in terms of margin.
David Adlington: It's roughly 80 80 basis points of margin.
David Adlington: So.
David Adlington: And therefore from here you need to go sequentially.
David Adlington: So if you've got 16, 8% and Youll missing Quito, but you still want to have it now a year over year Q2 versus Q2.
David Adlington: Uptake. This is exactly the challenge they have they are working on and.
David Adlington: This is where we will update you when we get into Q2, and then comps Q3.
David Adlington: This is more on the hospital side, the seasonally week kind of thing and then tie and kicks in Diana <unk> more because of the billing code and getting the contracts and shipping it in hosting revenue. It's more into Q4, so that one will be skewed more into Q4.
Speaker Change: Understood. That's helpful. Thank you.
Speaker Change: And I understand there's time for one last questioner.
Speaker Change: That will be Graham Doyle with UBS. Please go ahead.
Graham Doyle: Hi, guys. Thanks, a lot for taking my question.
Speaker Change: Just on Biopharma actually give some helpful slides now on 36 37, I suppose Michael just to contextualize when we look at Biopharma, We obviously had the.
Speaker Change: The Humira launch and now we have the tie in our timber launched they're very very different so as people are now looking at.
Speaker Change: Working how do we case study and launch so when we look at our trophy is that probably the way youre thinking about what the average loan should look like going forward and we should now start modeling your portfolio absorption and ascribing real value on that basis, just to get a sense of how you think that's positioned relative to say your humira and then pollyanna Tamara strategy.
Speaker Change: <unk>.
Speaker Change: Yes.
Speaker Change: Very good question and look.
Speaker Change: The very reason why you see.
Speaker Change: Us and.
Speaker Change: We're putting more and more biopharma charts into the deck.
Speaker Change: It's more an even richer information is exactly to help you on that one at the end of the day every molecule is different because it has a different therapeutic area I'm talking about U S.
And then we need to differentiate is it part b or part D and then which channel are.
Speaker Change: Are we playing and I think there has been also an evolution in the market. Even when you talk about Humira, where when we started the whole game everybody was talking about you need to be on the three national formularies of the Pbms and other than that nothing is going to happen.
Speaker Change: It doesn't seem to be the case.
Speaker Change: Remember the first couple of quarters, there was not a move in market share on the biosimilars rather the originator was occupying the entire market that changed a little bit it didn't pick up to the extend many have also other players have hoped initially but it did pick up and also in our case.
Speaker Change: <unk> always said economically we're not banking on that one but we are hosting revenue there because we chose different channels I was telling you on the on branded version going directly to payers and health plans and so on to four so in essence, driving our multichannel sales strategy that's in Europe.
Speaker Change: <unk> is a little different it's a much smaller originator market in the therapeutic area is the different one we are first to market and tire now I also acknowledge others are coming we still believe we have a very good position also when it comes to what forms we have SCE IV and.
Speaker Change: And then the vials pen injector and stuff now when it comes to <unk> B.
Speaker Change: If I say it will be more humira like don't get too crazy because humira was a very special case, but what I mean is also part b part D and multichannel kind of strategy on that one and we already know it will be very price competitive it will be.
Speaker Change: Last quarter, we have been discussing of a company.
Speaker Change: The one we also work with that they had an impairment in their books, we didn't have one which I told you. We are maybe have already incurred the different prices. So our strategy. There is maybe rather going on volume to get the contribution and then we will update you how it's going to work with the <unk> molecule.
Speaker Change: By molecule.
Speaker Change: That's super helpful. Thank you very much Michael.
Speaker Change: I would like to turn the conference back over to Michael Zhang for any closing remarks.
Speaker Change: No. Thank you operator, I think since we already extended our time I. Thank everybody and this is very busy earning season that you took the time and then we also have very very good question see you tomorrow in London. Thank you.
Speaker Change: Okay.
Speaker Change: We want to thank you for joining us and all the participants for taking part on this conference call Goodbye.
Speaker Change: Okay.
Speaker Change: Yes.
Speaker Change: [music].
Speaker Change: Okay.
Speaker Change:
Speaker Change: [music].
Speaker Change: Yeah.